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SUMMARY  As the incidence and already high mortality rates of 
malignant melanoma have been steadily increasing in recent de-
cades, the early detection and excision of malignant melanoma 
have imposed as the most important task. Staging of malignant 
melanoma is determined according to the level of invasion (Clark 
level) and vertical thickness (Breslow scale). Besides operative 
therapy, which is the only effective treatment for malignant melano-
ma, postoperative adjuvant chemotherapy, immunotherapy, radio-
therapy, and biologic therapy also are of great importance. In recent 
years, immunologic strategies including tumor vaccine and adju-
vant therapy with interferon-alfa have been attempted to improve 
survival of patients with more advanced malignant melanoma. A 
recent melanoma research has focused on target therapy such as 
immunotherapy (vaccines, monoclonal antibodies, dendritic cells) 
and gene therapy. Genetic immunization has become an attractive 
strategy for the development of melanoma vaccines, because a 
number of antigens recognized by cellular components of the im-
mune system have been identified at the molecular level. Numer-
ous chemotherapeutic agents have shown activity in the treatment 
of metastatic malignant melanoma, such as dacarbazine (dimethyl 
triazene imidazole carboxamide); other agents have been used, 
however, with less success. However, a very modest effect was 
recorded in advanced malignant melanoma. There are many ex-
perimental trials using combined therapy for malignant melanoma, 
including chemotherapy (dimethyl triazene imidazole carboxamide) 
and biologic therapy (interleukin (IL)-2, interferon (IFN)-gamma, 
IFN-alfa). The results obtained open particularly interesting pros-
pects in the field of malignant melanoma with high relevance for 
its development and progression. Molecular therapeutics and vac-
cine development will probably be an important focus for the future 
melanoma treatment.
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 INTRODUCTION
 Cutaneous melanoma is a tumor resulting 
from complex interactions between genetic, con-
stitutional and environmental factors (1-3). Its inci-
dence and already high mortality rates have been 
steadily increasing over recent decades. The risk 
factors associated with melanoma include fair 
complexion, a history of multiple childhood blister-
ing sunburns, an increased number of common 
acquired and dysplastic nevi, changes in a nevus, 
and family history of melanoma. Malignant mela-
noma (MM) is a skin tumor fatal for the majority of 
patients, and early detection is of high importance. 
This is supported by the fact that individuals with 
cutaneous melanoma have a higher survival rate 
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in developed countries, indicating that public edu-
cation about MM results in earlier diagnosis, treat-
ment and potential cure. 
 DIAGNOSTIC TECHNIQUES FOR MALIG-  
 NANT MELANOMA
 Different modalities are used to identify MM in 
clinical practice: ABCD method, total-body pho-
tography, skin surface microscopy, and machine 
dermatoscopy vision. Staging of MM is deter-
mined according to the level of invasion (Clark 
level) and vertical thickness (Breslow scale) (1-3). 
Clark’s method of microstaging is based on five 
levels of tumor invasion into the dermis and sub-
cutaneous fat, while Breslow’s method is based 
on vertical thickness (in millimeters) of the primary 
tumor from the epidermal granular layer (or the 
base of the lesion if the tumor is ulcerated) to the 
deepest identifiable contiguous melanoma cell 
(1-3). The American Joint Committee on Cancer 
(AJCC) has developed a staging system incorpo-
rating Breslow tumor thickness, Clark levels, and 
various other tumor characteristics. In 1969, clini-
cians and scientists from various disciplines and 
fields of research with a common interest in MM 
formed the EORTC Melanoma Group (MG), which 
has pursued a scientific approach to the develop-
ment of treatment for MM (4). 
 A systematic review of the literature reveals 
various diagnostic techniques for melanoma in-
cluding naked-eye clinical examination, clinical 
examination with the aid of total-body photo-
graphs, epiluminescence microscopy (ELM), digi-
tal ELM, computer-assisted techniques, near-in-
frared applications, teledermatology, etc. (1-3). 
Once a melanoma has been clinically identified 
and excised with adequate margins, it is important 
to detect any remaining or recurring tumor cells. 
One of the molecular diagnostic methods used for 
this purpose is reverse transcriptase polymerase 
chain reaction (RT-PCR), the most reliable and 
reproducible method for the detection of low-level 
disease. Therefore, RT-PCR may increase the 
power of minimal residual disease and micro- 
metastatic disease detection in some patients, re-
sulting in more accurate prognosis and/or improve-
ment in treatment timing or selection. Nucleic acid 
sequence-based amplification and RT-PCR both 
successfully amplified target RNA in peripheral 
blood samples from patients with MM, although its 
utility may be limited by the lack of automation and 
reproducibility. A novel imaging technique, near-
infrared technique for in vivo microscopic analysis 
of skin lesions including pigmented lesions, may 
aid in the early detection of clinically barely vis-
ible or nonpigmented melanomas and may facili-
tate preoperative noninvasive assessment of their 
margins (2,5). However, the rapid development 
of melanoma research produces new diagnostic 
techniques as well as potential new therapies. 
 EXPLORATION OF MODERN THERAPEU- 
 TIC METHODS FOR MALIGNANT MELANOMA
 Besides surgical therapy, which is the only ef-
fective treatment for MM, postoperative adjuvant 
chemotherapy, immunotherapy, radiotherapy, and 
biologic therapy are also important. Adjuvant in-
terferon-alfa-2b and various experimental mela-
noma vaccines are the most recent options that 
are currently being studied. Recent melanoma re-
search has focused on target therapy such as im-
munotherapy (vaccines, monoclonal antibodies, 
dendritic cells) and gene therapy, with the task to 
decrease their toxicity and enhance specific cyto-
toxicity.
 IMMUNOTHERAPY
 Different types of immunotherapy for MM are 
used, as yet only in the experimental phase, and 
the aim is to ensure a safe and efficient type of 
adjuvant therapy (Tables 1 and 2) (6). Nonspecific 
immunotherapy stimulates the reticuloendothelial 
system, whereas active specific immunization is 
considered to induce host response to tumor-as-
Table 1. Treatment for malignant melanoma ac-
cording to stages 
Therapy for primary melanoma:
- complete surgical excision of primary lesion
- elective lymph node dissection
- sentinel lymph node biopsy
Therapy for regional metastases:
- surgery 
- isolated limb perfusion
- adjuvant therapy (radiotherapy, chemotherapy, region- 
  al limb perfusion, IFN-alfa)
Therapy for distant metastases:
-  surgery
-  radiotherapy
-  chemotherapy (single-agent or combination chemo- 
   therapy) 
-  chemoimmunotherapy (IFN-alfa + chemotherapy)
-  biologic therapy (IFN-alfa, IL-2, IL-2+LAK cells, mono- 
    clonal antibodies, melanoma  vaccines)
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sociated antigens (Ag). Passive immunotherapy 
implies the introduction of in vitro activated anti-
tumor effector cells and includes two modalities 
of the use of gene transfer techniques: a genetic 
modification of effector cells and amplification 
of pre-effector cells. The effects of recombinant 
adenovirus and vaccinia virus vectors have been 
investigated (3). A new, polyvalent vaccine pro-
duced from allogeneic tumor inoculated with 
tumor-cell lysing vaccinia has been used. The 
administration of the cell lysate i.i. together with 
DETOX adjuvant (detoxicated endotoxin of cellu-
lar cytoskeleton), squalene oil, and emulsifier pro-
voked an initial response in 50% of patients (7). 
Another vaccine composed of allogeneic tumor 
cells and BCG resulted in better survival compared 
with control group, especially in men younger than 
57 and with less than five positive lymph nodes 
(8). The interest in specific active immunotherapy 
arose about 40 years ago due to a case of MM, 
which had regressed spontaneously after a blood 
transfusion. MM-associated antigens and antibod-
ies (Abs) reacting with melanoma cell membrane 
Ags have been identified in MM patients. One type 
of specific active immunotherapy are melanoma 
vaccines based on the melanoma cell-expression 
of human leukocyte antigens (HLA) and tumor-
associated Ags. MM vaccines such as purified 
gangliosides, shed antigens, mechanical or viral 
lysates, and allogeneic and autologous prepara-
tions of whole cells, mostly cytokines, have been 
tried to induce or enhance immunity against MM-
associated Ags. Multiple tumor Ags have been 
identified although little is known about which one 
would be most effective in cancer immunotherapy 
(9). To get an insight into the selection of appropri-
ate Ags, some authors measured immune reactivi-
ty of patients who had complete regression of mel-
anoma metastases. Studies revealed a melanoma 
Ag, identified as the BING-4 protein, encoded in a 
gene-rich region of the extended class II MHC, as 
an antigen with a potential use in immunotherapy 
of patients with MM (9). There also are other po-
tential vaccine components such as gangliosides, 
e.g., GD3, GM2 and GD2, that are abundantly ex-
pressed on the surface of malignant cell, suggest-
ing the potential anti-ganglioside antibody therapy 
(10). Koh et al. have reported on high in vivo anti-
tumor effects of anti-GM2 ganglioside Abs against 
tumor cells, which is currently used in clinical tri-
als for melanoma (10). Based on the expression 
of N-glycolyl-containing gangliosides and Ags on 
human melanoma cells, 1E10 anti-Id vaccine was 
used for the treatment of MM (11). The generation 
of 1E10 [gamma]-type anti-idiotype mAb (Ab2) 
specific to an Ab1 mAb, which is able to react spe-
cifically with the cells, performed in a clinical trial in 
20 patients with advanced MM, revealed the 1E10 
anti-Id vaccine to be a safe, well tolerated, and im-
munologically effective method (11). 
 Different antigens may be used as melanoma 
vaccine candidates alone or in combination with 
other tumor antigens, e.g., decapeptide ELA (ELA-
GIGILTV). The recombinant outer membrane pro-
tein A of Klebsiella pneumoniae (kpOmpA), P40, 
was recently shown to target dendritic cells and to 
induce peptide-specific CTLs, suggesting the ad-
juvant role of P40 mixed or chemically conjugated 
to ELA, and P40/ELA as an important melanoma 
vaccine candidate (12). 
 Identification of tumor antigens and their op-
timal antigenic peptides has raised hope for the 
development of peptide-based immunothera-
peutic vaccine strategies for human melanoma. 
However, synthetic peptides alone are not immu-
nogenic enough and an appropriate formulation 
is critical for the elaboration of peptide vaccines. 
Table 2. Immunotherapeutic strategies for malig-
nant melanoma
IFN:    
 IFN-alfa as single agent or in combination with 
   chemotherapy
Interleukins:  
   IL-2 
   IL-2 plus LAK cells
   IL-2 plus IFN
Monoclonal antibodies:
    MAbs against melanoma-associated Ags (peptidogly- 
   cans, transferrin receptor-related Ags, glycoproteins, 
    high-molecular melanoma-associated Ags, sialoglyco- 
    proteins, gangliosides)
Melanoma vaccines:
-  polyvalent vaccine with whole melanoma cells (e.g., 
  autologous -  autologous vaccines + haptens /DNP, 
   BCG/ or cytokines /IL-2, GM-CSF/)
- allogeneic vaccine (e.g., polyvalent melanoma cell 
   vaccine:   PMCV/Cancer-Vex Melacine)
    - cell lysate (e.g., vaccinia melanoma cell lysate 
          (VMCL))
     -  partially purified Ags (e.g., shed-Ag vaccine  and 
       mechanical cell lysates)
   - univalent vaccine: purified Ags (e.g., GM2- 
       KLH/QS - 21); peptide 
  -  Ags (e.g., tyrosinase, gp-100)
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The results reported from a study indicated that a 
single palmitoyl-lysine chain is enough to assure 
immunogenicity of a given peptide. The presence 
of a lipid tail bypasses the need of an adjuvant. 
Identification of Melan-A/MART-1 antigen immu-
nodominant peptide analog supported the selec-
tion of MART-lipopeptide melanoma vaccine for 
evaluation in a clinical trial (13).
 Adoptive immunotherapy implies passive 
transfer of activated immune cells to the tumor pa-
tient in order to stimulate tumor regression, e.g., 
lymphoid cells, IL-2, tumor infiltrating lymphocytes 
(TIL), lymphoid cells from regional lymph nodes, 
and T-cells that are immunospecific for reactivity 
to MM (14). Lymphoid cells recognize antigen and 
produce cytokines (TNF and IFN-gamma, GM-
SCF), which can directly destroy the tumor and 
attract other host cells to mediate tumor regres-
sion. An example of such therapy is the use of IL-2 
(acts as a growth factor for the cells) with infusion 
of lymphoid activated cells forming so-called lym-
phokine-activated killer (LAK) cells, with response 
in 15% of patients (15).
 GENE THERAPY
 Gene therapy is a new therapeutic method in 
the treatment of MM, which attempts to transform 
genetic material into human cells. Various gene 
therapy strategies for MM are being evaluated in 
multiple clinical trials all over the world. There are 
gene modified cancer vaccines (GMTV) modified 
with genes encoding cytokines or costimulatory 
molecules and dendritic cells modified with genes 
encoding tumor antigens or immunostimulatory 
factors (16).
 The results reported from a study indicate that 
two genes are implicated in the pathogenesis of 
melanoma, i.e. CDKN2A and CDK4. The CDKN2A 
gene is a tumor suppressor gene with germline 
mutations detected in 20% of melanoma-prone 
families, and is an appealing candidate for MM 
susceptibility (17). The CDK4 gene is an oncogene 
with cosegregating germline mutations detected in 
only three kindreds worldwide. Thus, the pheno-
type observed in melanoma-prone CDK4 families 
appears to be more complex than just the CDK4 
mutation. Although CDK4 is a melanoma suscepti-
bility gene, it plays a minor role in hereditary mela-
noma. Suicide gene therapy in combination with 
prodrugs represents an attractive approach to the 
treatment of cancer but it is limited by the difficulty 
in targeting tumor cells, especially those at distant 
metastases associated with the most complex tu-
mors (18). For this reason, attempts to stimulate 
global anti-tumor immune responses at the sites 
of effective suicide gene/prodrug-mediated tumor 
cell destruction are appealing. It included a gene 
coding for secreted secondary lymphoid tissue 
chemokine (SLC) along with the herpes simplex 
virus thymide kinase (HSV-TK) gene, and a bicis-
tronic vector for anti-tumor gene therapy in con-
junction with the prodrug ganciclovir (GCV). They 
mediated a greatly enhanced anti-tumor effect in 
the murine B16 melanoma tumor model and the 
obtained enhanced antitumor effect was the result 
of a strong induced cytotoxic T-lymphocyte (CTL) 
immune response resulting from the recruitment of 
immune cells to the site of HSV-TK/GCV-induced 
tumor destruction by the potent chemokine SLC 
(18). 
 Attempts have been made to transfer geneti-
cally modified TIL cells secreting TNF that selec-
tively migrates to the tumor site, and tumor trans-
fer employing an in vivo model, i.e. by CT-guided 
intratumor DNA inoculation associated with lipo-
somes was also done (19).  
 Certain genes may suppress growth and induce 
apoptosis in a variety of human tumor cell lines. 
Subtraction hybridization identified mda-7, a mela-
noma differentiation associated (mda) gene, as a 
negative regulator of its growth and progression. 
Mda-7 is a ubiquitous inhibitor of growth in diverse 
human cancers and may have direct translational 
potential for gene-based therapy (20). Thus, ecto-
pic transfer of mda-7 in vitro suppressed growth 
and induced apoptosis in a variety of human tumor 
cell lines but not normal cells (21). The expression 
of mda-7 inversely correlates with melanoma de-
velopment and progression, and increasingly re-
duces expression in radial growth phase, vertical 
growth phase and metastatic melanoma.
 After treatment with a combination of fibroblast 
interferon (IFN-beta) and the protein kinase C 
activator mezerein (MEZ), the human melanoma 
cell growth is arrested irreversibly, they lose their 
tumorigenic potential and terminally differentiate 
(20). The combination of IFN-beta plus MEZ re-
programs metastatic MM cells to undergo a loss of 
cancerous potential and to terminally differentiate. 
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 In genetic therapy for MM, mda-7 has an im-
portant role and study results support future ap-
plications of mda-7 in gene-based therapy for MM 
(20). Intracellular MDA-7 protein is found in most 
of the melanocyte/melanoma cell lines and its se-
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cretion is readily detected following Ad.mda-7 in-
fection of both melanocytes and melanoma cells. 
Downregulation of MDA-7 protein expression in 
primary melanomas facilitates progression to in-
vasive and metastatic stages, supporting develop-
ment of Ad-mda7 as gene therapy for advanced 
melanoma (21).  
 Genetic immunization has become attractive 
for the development of melanoma vaccines, and a 
number of antigens recognized by cellular compo-
nents of the immune system have been identified 
at the molecular level (22). These melanoma anti-
gens include normal cellular proteins such as the 
tyrosinase family of enzymes involved in melanin 
synthesis, expressed in melanocytes and melano-
ma cells. The mechanisms maintaining peripheral 
tolerance to self-Ags present a major obstacle for 
the development of antigen-specific melanoma 
vaccines, presumably because self-Ags are not 
able to stimulate CD4 T-helper response (22). 
Analysis of melanosomal enzyme tyrosinase-re-
lated protein 2 (TRP2) expressed by melanocytes 
and most melanoma cells and genetic immuni-
zation of mice with cDNA encoding a fusion pro-
tein between enhanced green fluorescent protein 
(EGFP) and autologous murine TRP2 (EGFP.
mTRP2) resulted in stimulation of TRP2-reactive 
T cell. The immunization with EGFP.mTRP2 ef-
fectively protected mice against metastatic growth 
of B16 melanoma. The study results showed that 
tumor vaccines consisting of self-antigens linked 
to immunogenic helper sequences could be suc-
cessfully applied to immunotherapy for melanoma 
(22). 
 There are also other gene therapy mecha-
nisms based on cell tumor, which may be used in 
the prevention of metastatic melanoma. In tumor 
cell invasion, the spread of MM and the degrada-
tion of extracellular matrix proteins matrix metal-
loproteinases are involved, such as tissue inhibi-
tor of metalloproteinase-1 (TIPM-1) used as gene 
therapy, which prevents tumor cell invasion and 
metastasis by preserving extracellular matrix in-
tegrity (23). Experimental examination on mice 
showed that pulmonary metastases were signifi-
cantly reduced after 4 weeks of TIMP-1 treatment 
(23).
 MOLECULAR BIOLOGY
 Convergent evidence from genetic linkage 
studies of melanoma-prone families and molecu-
lar analyses of regulators of cell cycle checkpoints 
have led to the discovery of a major gene for MM 
and to elucidation of its probable mechanism of 
action (24). There exists a large body of literature 
characterizing p16 deletions and mutations in a 
wide range of cancers and in familial melanoma. 
Alterations in the p16 gene are very common in 
cultured melanoma cells, the rate averaging ap-
proximately 70% across numerous studies (24). 
Cell progression through the G1 phase of the cell 
division cycle is dependent on molecular com-
plexes formed from the catalytic subunit, CDK4 
(cyclin-dependent kinase 4), and the regulatory 
subunit, cyclin D1. 
 Approximately 10% of MM patients have family 
histories of the disease, and approximately 20% of 
families with a predisposition to melanoma have 
germline mutations in the CDKN2A tumor-sup-
pressor gene, also known as p16, p16 INK4a, or 
MTS1, which encodes a cell-cycle regulator that 
inhibits activities of protein kinases cdk4 and cak6 
(25). Some authors examined experimental mod-
els of expression of different molecules on MM 
cells which promote tumor activation and vascu-
larization. Membrane-type metalloproteinase-1 
(MT1-MMP) is a transmembrane metalloprotein-
ase overexpressed in tumors, which plays a major 
role in the first step of pro-MMP-2 activation, lead-
ing to the generation of an intermediate 62 kDa 
species (26). The second step of MMP-2 activa-
tion that yields the mature form is less understood 
and could involve an autocatalytic process and/or 
the activity of the plasminogen/plasmin system. It 
has been revealed on an experimental model that 
MT1-MMP expression by tumor cells promotes 
tumor vascularization. Different cytokines may be 
involved in tumor activities, such as hepatocyte 
growth factor/scatter factor (HGF/SF), a multi-
functional cytokine capable of eliciting mitogenic, 
mutagenic and morphogenetic activities in tumor 
development and metastasis. Members of the 
mitogen-activated protein kinase (MAPK) super-
family, including p38 kinase and stress-activated 
protein kinase/c-Jun NH2-terminal kinase (SAPK/
JNK), play a central role in mediating cellular re-
sponse to environmental stress, growth factors 
and cytokines (27).  Notably, the p38 kinase-spe-
cific inhibitor was able to block melanoma cell pro-
liferation but not motility. Recio et al. have shown 
that the ATF-2 transcription factor becomes acti-
vated by HGF/SF through p38 MAPK and SAPK/
JNK. Moreover, the p38-ATF-2 pathway can help 
mediate proliferation signals in tumor cells through 
transcription activation of key cell cycle regulators 
(27).
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 Numerous studies have demonstrated the ex-
pression of surviving, 16.5 kDa protein, in MM, 
which inhibits the two early apoptotic enzymes 
caspase-3 and caspase-7, and thus prevents pro-
grammed cell death (28). Surviving may act simul-
taneously with the bel-2 family proteins, but has 
a different apoptosis inhibitory mechanism. As a 
positive correlation between surviving expression 
and tumor grading, and its indication of tumor re-
currence after resection or chemotherapy, it could 
be potentially diagnostic and a prognostic marker 
in monitoring MM patients (28). 
 It is also important to mention the role of B-raf 
oncogene (BRAF) mutations in primary cutaneous 
MM. Namely, somatic mutations of BRAF kinase, 
a component of the Ras-mitogen-activated pro-
tein/extracellular signal-regulated kinase kinase-
mitogen-activated protein kinase pathway, are 
frequently reported (>65%) in MM and nevi, with 
a relation to tumor progression and an effect on 
disease outcome (29). 
 CHEMOTHERAPY
 Numerous chemotherapeutic agents have 
shown activity in the treatment of metastatic MM. 
The most widely used chemotherapeutic is dacar-
bazine (dimethyl triazene imidazole carboxamide; 
DTIC), especially in previously untreated patients 
and those with nonvisceral disease (MM of the 
skin, soft tissue or lymph nodes), with a response 
rate of 15%-20% (30). However, a very modest ef-
fect was recorded in advanced MM. Other chemo-
therapeutics that have been tried in the treatment 
of stage III MM are tamoxifen, thymopectin, car-
mustine (BCNU), cisplatin, bleomycin, yemustin, 
vincristine, carboplatin, and fotemustine (31-34). 
They can be combined with IL-2 and IFN-alfa-
chemoimmunotherapy. Some researchers have 
looked for ways to make the existing chemothera-
peutic agents more effective. 
 Different plasma membrane enzymes may 
have an important role in cellular thiols expressed 
in tumor cells. Thus, the [gamma]-glutamyl trans-
peptidase (GGT) enzyme is often expressed in MM 
and other malignant tumors, although its levels 
may vary widely among different tumors or cells of 
the tumor, but plays a crucial role in cellular han-
dling of thiols (35). Thiols are recognized factors in 
the modulation of cell sensitivity to platinum-based 
anticancer drugs, and thiol redox status can affect 
important functions both intracellularly and extra-
cellularly.  
 COMBINED THERAPY 
 (BIOCHEMOTHERAPY)
 There are many experimental trials using com-
bined therapy for MM including chemotherapy 
(DTIC) and biologic therapy (IL-2, IFN-alfa, IFN-
gamma). High-dose IFN-alfa-2b is a pleiotropic 
cytokine with a potential antitumor effect, and is 
the only Food and Drug Administration approved 
adjuvant treatment for MM patients who are at a 
high risk of recurrence (36). Surgically resected 
melanoma patients with high-risk features com-
monly receive adjuvant therapy with IFN-alfa-2b 
combined with radiotherapy, in spite of its high tox-
icity. A retrospective chart review study of patients 
treated with IFN during radiotherapy or within one 
month of its completion elucidated the potential for 
enhancement of radiation toxicity by IFN (37). Al-
though IFN may have an impact on disease-free 
survival, the longterm impact is uncertain, and a 
recent systematic review of randomized controlled 
trials of MM demonstrated no clear benefit on over-
all survival (38-40). IFN-gamma is another pleio-
tropic cytokine with antitumor activities, including 
cell growth inhibition, natural killer (NK) cell and 
CTL activation, and angiogenesis inhibitory activ-
ity. These activities are thought to be involved in 
its antitumor activity. Thus, IFN-gamma prevents 
B16 MM experimental metastasis by directly inhib-
iting cell growth although antitumor host functions 
were noted.  There is circumstantial evidence that 
points to a potentially harmful effect of IFN-alfa-
2b on platelet function and severe impairment of 
platelet aggregation, which appears to be dose-
dependent and cumulative dose-dependent. It is 
supposed that the antiaggregation activity may be 
the mechanism by which IFN delays, reduces, or 
prevents the formation of melanoma metastases. 
 TNF, IFN-gamma, GM-CSF and IL-1 have a 
strong modulatory and immunoproliferative ac-
tion, thus being potentially immunotherapeutic. 
Cytokine therapy is associated with significant 
reversible toxicity; however, it results in a high 
degree of tumor destruction. There has been a 
recent emphasis on the investigation of immuno-
therapy approaches to melanoma treatment. Al-
though the benefit of these approaches has been 
uncertain so far, further investigation in this area 
as well as combination immunotherapy may prove 
valuable. The role of biochemotherapy (combined 
chemotherapy) remains to be seen as it has so far 
showed good response rates but not much impact 
on overall survival.
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 CONCLUSION
 The many successful results obtained in MM 
patients open highly interesting prospects of great 
importance for melanoma development, progres-
sion and management. The experimental results 
may influence the molecule expression in normal 
melanocytes and nevi, and increasingly reduce 
expression in radial growth phase, vertical growth 
phase and metastatic melanoma. Molecular thera-
peutics and vaccine development will be an im-
portant focus for the next decade as is the ever 
challenging task of identifying a systemic adjuvant 
therapy regimen for high-risk melanoma. The re-
sults recorded in many studies show that tumor 
vaccines consisting of self-antigens linked to im-
munogenic helper sequences could be success-
fully applied to immunotherapy for MM and provide 
a scientific basis for the translation of this strategy 
into future clinical investigations.
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